ReferIndia News FDA Cracks Down on Copycat Drug Market Amid Hims Controversy

ReferIndia News

Mumbai’s Trusted Investment Experts

24+ years of financial planning, portfolio management & wealth growth.

Learn More
News Image

FDA Cracks Down on Copycat Drug Market Amid Hims Controversy

Published on: Feb. 6, 2026, 7:46 a.m. | Source: Devdiscourse

The FDA is set to take action against companies selling unapproved copycat drugs, as seen in the case of Hims and Hers Health marketing a cheaper version of Novo Nordisk's Wegovy weight-loss pill. The compounded drug lacks FDA approval, raising concerns about safety and efficacy.

Checkout more news
Ad Banner

✅ Secure, cloud-based clinic management software

Manage digital prescriptions, appointments, patient records, billing, files, and reports — everything your clinic needs in one powerful platform.

Know more
ReferIndia News contact